ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Clin Infect Dis · 2026-10-28

In 833 adults aged ≥50, giving adjuvanted RSVPreF3 with an XBB.1.5 COVID-19 mRNA vaccine met non-inferiority for RSV-A and RSV-B titres vs sequential dosing but marginally missed it for SARS-CoV-2 (GMT ratio 1.31, 95% CI 1.13–1.51); safety was similar.

RCTn = 833
Bonten et al. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial
Infectious diseases · Clin Infect Dis · 2026-10-07

Phase 3 open-label RCT in 530 adults ≥50 years: giving adjuvanted RSVPreF3 with recombinant zoster vaccine on the same day was non-inferior to a month apart for RSV-A/B and anti-gE responses; solicited systemic AEs 73.6% vs 60.4% after visit 1.

RCTn = 530
Roussy et al. Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age
Infectious diseases · Clin Infect Dis · 2026-10-07

Phase 3 open-label non-inferiority RCT in 1112 adults ≥60 years: co-administering adjuvanted RSVPreF3 and PCV20 was non-inferior to giving them 1 month apart for RSV-A, RSV-B and all 20 pneumococcal serotype responses, with similar safety.

RCTn = 1,112
Leroux-Roels et al. Immunogenicity and Safety of Co-administration of Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine With 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: A Randomized, Non-inferiority Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.